Acrivon Therapeutics Inc (NASDAQ: ACRV) kicked off on Friday, down -6.00% from the previous trading day, before settling in for the closing price of $2.0. Over the past 52 weeks, ACRV has traded in a range of $1.05-$8.74.
A company in the Healthcare sector has dropped its sales by -74.96% annually for the last half of the decade. While this was happening, its average annual earnings per share was recorded 6.77%. With a float of $22.31 million, this company’s outstanding shares have now reached $31.45 million.
Acrivon Therapeutics Inc (ACRV) Insider Updates
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Acrivon Therapeutics Inc is 29.07%, while institutional ownership is 48.70%. The most recent insider transaction that took place on Apr 30 ’25, was worth 617,412. In this transaction 10% Owner of this company sold 437,881 shares at a rate of $1.41, taking the stock ownership to the 3,403,025 shares. Before that another transaction happened on May 01 ’25, when Company’s 10% Owner sold 298,886 for $1.34, making the entire transaction worth $400,507. This insider now owns 3,104,139 shares in total.
Acrivon Therapeutics Inc (ACRV) Performance Highlights and Predictions
In the latest quarterly report, which was put into the public domain on 9/30/2024, the organization reported -0.59 earnings per share (EPS), higher than consensus estimate (set at -0.59) by 0. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.57 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 6.77% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 3.18% during the next five years compared to -74.96% drop over the previous five years of trading.
Acrivon Therapeutics Inc (NASDAQ: ACRV) Trading Performance Indicators
Take a look at Acrivon Therapeutics Inc’s (ACRV) current performance indicators. Last quarter, stock had a quick ratio of 10.31.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.25, a number that is poised to hit -0.59 in the next quarter and is forecasted to reach -2.15 in one year’s time.
Technical Analysis of Acrivon Therapeutics Inc (ACRV)
Let’s dig in a bit further. During the last 5-days, its volume was 3.35 million. That was better than the volume of 0.77 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 20.42%.
During the past 100 days, Acrivon Therapeutics Inc’s (ACRV) raw stochastic average was set at 48.03%, which indicates a significant increase from 14.69% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.1664 in the past 14 days, which was higher than the 0.1227 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.7758, while its 200-day Moving Average is $2.3533. However, in the short run, Acrivon Therapeutics Inc’s stock first resistance to watch stands at $2.0106. Second resistance stands at $2.1413. The third major resistance level sits at $2.2565. If the price goes on to break the first support level at $1.7647, it is likely to go to the next support level at $1.6495. Assuming the price breaks the second support level, the third support level stands at $1.5188.
Acrivon Therapeutics Inc (NASDAQ: ACRV) Key Stats
The company with the Market Capitalisation of 59.14 million has total of 31,456K Shares Outstanding. Its annual sales at the moment are 0 K in contrast with the sum of -80,560 K annual income. Company’s last quarter sales were recorded 0 K and last quarter income was -21,010 K.
